Concord Biotech Stock Falls to 52-Week Low of Rs.1325 Amidst Market Pressure

1 hour ago

Share Via

Concord Biotech’s shares touched a fresh 52-week low of Rs.1325 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock’s intraday movement reflected a drop of 3.93%, underperforming the Pharmaceuticals & Biotechnology sector by nearly 4%.

Intraday Price Movement and Market Context

On 17 Dec 2025, Concord Biotech’s stock recorded an intraday low of Rs.1325, representing its lowest price point in the past year. This decline occurred despite a positive start to the trading session, with the Sensex opening 176.40 points higher. However, the benchmark index reversed course, falling by 296.61 points to trade at 84,559.65, down 0.14% by midday. The Sensex remains close to its 52-week high of 86,159.02, trading 1.89% below that peak and maintaining a bullish stance above its 50-day and 200-day moving averages.

In contrast, Concord Biotech’s share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum relative to its recent trading history.

Performance Over the Past Year

Over the last 12 months, Concord Biotech’s stock has recorded a return of -35.21%, a stark contrast to the Sensex’s positive 4.80% performance over the same period. The stock’s 52-week high was Rs.2451.65, indicating a substantial reduction in value from its peak. This underperformance extends beyond the last year, with the stock lagging behind the BSE500 index over one, three years, and the most recent three-month period.

Financial Metrics Reflecting Recent Trends

Concord Biotech’s financial data over recent quarters and years highlights several key points. The company’s operating profit has shown a compound annual rate of change of -0.48% over the last five years, indicating limited growth in core profitability. The latest quarterly Profit Before Tax (PBT) stood at Rs.72.33 crores, reflecting a decline of 32.1% compared to the average of the previous four quarters.

Operating cash flow for the year is reported at Rs.244.52 crores, marking the lowest level in recent periods. The Profit After Tax (PAT) for the latest six months is Rs.107.64 crores, showing a contraction of 30.7% relative to prior comparable periods. These figures suggest a subdued earnings environment for the company in the near term.

Valuation and Efficiency Indicators

The company’s return on equity (ROE) is recorded at 17.7%, which is relatively high and indicative of management’s efficiency in generating profits from shareholder equity. However, the stock’s price-to-book value ratio stands at 7.8, suggesting a valuation that is considered expensive when compared to historical averages and peer companies within the Pharmaceuticals & Biotechnology sector.

Despite the elevated valuation metrics, Concord Biotech’s stock price has not reflected positive returns, with profits showing a marginal decline of 1.2% over the past year. This divergence between valuation and earnings performance may be contributing to the downward pressure on the share price.

Capital Structure and Shareholding

The company maintains a low debt-to-equity ratio, averaging zero, which indicates a conservative capital structure with minimal reliance on external borrowings. Promoters remain the majority shareholders, maintaining significant control over the company’s strategic direction.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Concord Biotech’s recent share price performance has lagged behind sector averages. The stock’s underperformance relative to the sector by approximately 3.95% on the day of the new low highlights the challenges faced in maintaining momentum amid broader market conditions.

The Sensex’s current position near its 52-week high contrasts with Concord Biotech’s downward trajectory, underscoring the divergence between the company’s stock and the broader market indices. This gap is further emphasised by the stock’s position below all major moving averages, while the Sensex maintains a bullish technical stance.

Summary of Key Price and Performance Data

• New 52-week low price: Rs.1325

• Intraday decline: 3.93%

• Underperformance versus sector: 3.95%

• One-year stock return: -35.21%

• Sensex one-year return: 4.80%

• 52-week high price: Rs.2451.65

• Operating profit CAGR (5 years): -0.48%

• Latest quarterly PBT: Rs.72.33 crores (-32.1%)

• Operating cash flow (yearly): Rs.244.52 crores (lowest recent level)

• PAT (latest six months): Rs.107.64 crores (-30.7%)

• ROE: 17.7%

• Price to book value: 7.8

• Debt to equity ratio: 0 (average)

These figures collectively illustrate the current state of Concord Biotech’s stock and financial position, reflecting pressures on price and earnings despite strong management efficiency and a conservative balance sheet.

Conclusion

Concord Biotech’s stock reaching a 52-week low of Rs.1325 marks a notable point in its recent trading history. The decline is set against a backdrop of subdued earnings growth, valuation considerations, and sector underperformance. While the broader market indices maintain strength, Concord Biotech’s share price continues to face downward pressure, trading below all key moving averages and reflecting a challenging environment for the company’s stock in the current market cycle.

Only ₹14,999 - Get MojoOne + Stock of the Week for 2 Years PLUS 6 Months FREE Claim 83% OFF →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE